Tempest Therapeutics (TPST) vs Exicure (XCUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Exicure is the larger company by market cap ($5.9 million vs $5.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TPST | XCUR |
|---|---|---|
| Share price | $0.287 | $0.9001 |
| Market cap | $5.74M | $5.89M |
| 1-day change | -6.18% | -12.82% |
| YTD return | -90.00% | — |
| 1-year return | -91.80% | — |
| 5-year return | -99.77% | — |
| EPS (TTM) | $-3.16 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-26.26M | $-4.95M |
| 52-week high | $4.22 | $9.48 |
| 52-week low | $0.28 | $0.777 |
| Distance from 52-week high | -93.20% | -90.51% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +2339.02% | — |
| Average volume | 2.56M | 53.56K |
| Shares outstanding | 20.00M | 6.55M |
| Employees | 4 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Exicure
XCUR stock →Exicure, Inc. does not have significant operations.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
TPST vs XCUR FAQ
Which is bigger, Tempest Therapeutics or Exicure?
Exicure (XCUR) is larger, with a market capitalization of $5.89M compared with $5.74M for Tempest Therapeutics (TPST).
Are Tempest Therapeutics and Exicure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.